Tarsus Pharmaceuticals Inc expected to post a loss of 97 cents a share - Earnings Preview

Tarsus Pharmaceuticals

05/11/2022 03:07

* Tarsus Pharmaceuticals Inc  TARS.OQ   TARS.O  is expected
to show a rise in quarterly revenue when it reports  results on
November 7 (estimated). 
    * The Irvine California-based  company is expected to report
 a
135.2% increase in revenue to $2.917 million from $1.24 million
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Tarsus
Pharmaceuticals
Inc is for a loss of 97 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $45​, above​ its last closing price
of $17.98. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.61       -0.59      -0.24     Beat    59.4
 Mar. 31 2022  -1.06       -0.92      -0.98     Missed  -6.8
 Dec. 31 2021  -0.76       -0.73      -0.72     Beat    1​
 Sep. 30 2021  -0.41       -0.43      -0.76     Missed  -75.1
 ​​Jun.        -0.40       -0.48      0.33      Beat    169.2
 30 2021                                                
 Mar. 31 2021  -0.73       -0.64      0.47      Beat    173.4​
 Dec. 31 2020              -0.66      -0.68     Missed  -3
 Sep. 30 2020  -0.53       -0.53      -3.71     Missed  -600
 This summary was machine generated November 5 at 03:06 GMT.  All
figures in US dollars  unless otherwise stated